The Effect of High Dose N-acetylcysteine on Airtrapping and Airway Resistance in Chronic Obstructive Pulmonary Disease (COPD) Patients

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to investigate the add-on effect of high dose NAC (600mg tablet twice daily) on reduction of airtrapping and airway resistance in stable COPD patients as well as to study it's effect in reducing exacerbation, improving exercise capacity and quality of life in stable COPD patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kwong Wah Hospital
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Spirometry diagnosed COPD with FEV1/FVC ratio less than 70% and FEV1 less than 80% predicted

• clinically stable and exacerbation free in the past 4 weeks

• history of at least one COPD exacerbation in the past one year

Exclusion Criteria:

• patients allergic or intolerant to NAC

• Recent use of NAC in the past one month

• history of asthma, non COPD respiratory disorders like bronchiectasis, pneumoconiosis or any active pulmonary infection

• patients on long term steroid

• patients on long term oxygen therapy or non invasive ventilation